← All trials
NCT05480436
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 5, 2022
- Primary completion
- Jan 30, 2023
- Completion date
- Jul 30, 2023
- First posted
- Jul 29, 2022
- Last posted
- Aug 30, 2022
- Enrollment
- 1200
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- China National Biotec Group Co., LtdLead sponsor
- Central South UniversityCollaborator
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaCollaborator
- Government of ChinaOverall official - principal investigator
- China National Biotec Group Co., LtdCollaborator
- Beijing Tiantan Bio Co., LtdCollaborator
- Chengdu Institute of Biological Products Co.,Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.